111 related articles for article (PubMed ID: 37139547)
21. Computational repurposing approach for targeting the critical spike mutations in B.1.617.2 (delta), AY.1 (delta plus) and C.37 (lambda) SARS-CoV-2 variants using exhaustive structure-based virtual screening, molecular dynamic simulations and MM-PBSA methods.
Ebrahimi M; Karami L; Alijanianzadeh M
Comput Biol Med; 2022 Aug; 147():105709. PubMed ID: 35728285
[TBL] [Abstract][Full Text] [Related]
22. Identification of novel small molecule inhibitors for endoplasmic reticulum oxidoreductase 1α (ERO1α) enzyme: structure-based molecular docking and molecular dynamic simulation studies.
Albassam H; Mehta CH; Nayak UY
J Biomol Struct Dyn; 2022; 40(23):13218-13232. PubMed ID: 34606425
[TBL] [Abstract][Full Text] [Related]
23. Repurposing of FDA approved drugs and their validation against potential drug targets for
Kesharwani A; Chaurasia DK; Katara P
J Biomol Struct Dyn; 2022 Sep; 40(14):6255-6271. PubMed ID: 33525976
[No Abstract] [Full Text] [Related]
24. ER-Resident Transcription Factor Nrf1 Regulates Proteasome Expression and Beyond.
Hamazaki J; Murata S
Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32456207
[TBL] [Abstract][Full Text] [Related]
25. Rutaretin1'-(6″-sinapoylglucoside): promising inhibitor of COVID 19 m
Thodi RC; Ibrahim JM; Surendran VA; Nair AS; Sukumaran ST
J Biomol Struct Dyn; 2022; 40(23):12557-12573. PubMed ID: 34528865
[TBL] [Abstract][Full Text] [Related]
26. Could the FDA-approved anti-HIV PR inhibitors be promising anticancer agents? An answer from enhanced docking approach and molecular dynamics analyses.
Arodola OA; Soliman ME
Drug Des Devel Ther; 2015; 9():6055-65. PubMed ID: 26622167
[TBL] [Abstract][Full Text] [Related]
27. A dynamic simulation study of FDA drug from zinc database against COVID-19 main protease receptor.
Mathpal S; Joshi T; Sharma P; Joshi T; Pundir H; Pande V; Chandra S
J Biomol Struct Dyn; 2022 Feb; 40(3):1084-1100. PubMed ID: 32940134
[TBL] [Abstract][Full Text] [Related]
28. The endoplasmic reticulum stress/unfolded protein response in gliomagenesis, tumor progression and as a therapeutic target in glioblastoma.
Peñaranda Fajardo NM; Meijer C; Kruyt FA
Biochem Pharmacol; 2016 Oct; 118():1-8. PubMed ID: 27106078
[TBL] [Abstract][Full Text] [Related]
29. Screening of FDA approved drugs for finding potential inhibitors against Granzyme B as a potent drug-repurposing target.
Ikram S; Ahmad J; Durdagi S
J Mol Graph Model; 2020 Mar; 95():107462. PubMed ID: 31786094
[TBL] [Abstract][Full Text] [Related]
30. Peptide-like and small-molecule inhibitors against Covid-19.
Pant S; Singh M; Ravichandiran V; Murty USN; Srivastava HK
J Biomol Struct Dyn; 2021 May; 39(8):2904-2913. PubMed ID: 32306822
[TBL] [Abstract][Full Text] [Related]
31. Drug repurposing studies targeting SARS-CoV-2: an ensemble docking approach on drug target 3C-like protease (3CL
Koulgi S; Jani V; Uppuladinne M; Sonavane U; Nath AK; Darbari H; Joshi R
J Biomol Struct Dyn; 2021 Sep; 39(15):5735-5755. PubMed ID: 32679006
[TBL] [Abstract][Full Text] [Related]
32. Enfuvirtide, an HIV-1 fusion inhibitor peptide, can act as a potent SARS-CoV-2 fusion inhibitor: an
Ahmadi K; Farasat A; Rostamian M; Johari B; Madanchi H
J Biomol Struct Dyn; 2022 Aug; 40(12):5566-5576. PubMed ID: 33438525
[TBL] [Abstract][Full Text] [Related]
33. Molecular mechanism of inhibition of COVID-19 main protease by β-adrenoceptor agonists and adenosine deaminase inhibitors using
Venugopal PP; Chakraborty D
J Biomol Struct Dyn; 2022 Jul; 40(11):5112-5127. PubMed ID: 33397209
[TBL] [Abstract][Full Text] [Related]
34. Identification of some novel oxazine substituted 9-anilinoacridines as SARS-CoV-2 inhibitors for COVID-19 by molecular docking, free energy calculation and molecular dynamics studies.
Rajagopal K; Varakumar P; Aparna B; Byran G; Jupudi S
J Biomol Struct Dyn; 2021 Sep; 39(15):5551-5562. PubMed ID: 32720578
[TBL] [Abstract][Full Text] [Related]
35. In silico identification of potential Hsp90 inhibitors via ensemble docking, DFT and molecular dynamics simulations.
Rezvani S; Ebadi A; Razzaghi-Asl N
J Biomol Struct Dyn; 2022; 40(21):10665-10676. PubMed ID: 34286666
[TBL] [Abstract][Full Text] [Related]
36. RNR inhibitor binding studies of
Ravindranath BS; Vishnu Vinayak S; Chandra Mohan V
J Biomol Struct Dyn; 2022; 40(19):9416-9428. PubMed ID: 34032189
[No Abstract] [Full Text] [Related]
37.
Sarkar S; Kandasamy T; Shome R; Ghosh SS
J Biomol Struct Dyn; 2023 Oct; ():1-12. PubMed ID: 37855370
[TBL] [Abstract][Full Text] [Related]
38. Unveiling the potential of recently FDA-approved drugs as quorum sensing inhibitors against
Dey D; Kumar A
J Biomol Struct Dyn; 2024 Jan; ():1-18. PubMed ID: 38230441
[TBL] [Abstract][Full Text] [Related]
39. Design, synthesis, and molecular dynamics simulation studies of quinoline derivatives as protease inhibitors against SARS-CoV-2.
Singh VK; Chaurasia H; Kumari P; Som A; Mishra R; Srivastava R; Naaz F; Singh A; Singh RK
J Biomol Struct Dyn; 2022; 40(21):10519-10542. PubMed ID: 34253149
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of calpain-1 stabilizes TCF11/Nrf1 but does not affect its activation in response to proteasome inhibition.
Nowak K; Taubert RM; Haberecht S; Venz S; Krüger E
Biosci Rep; 2018 Oct; 38(5):. PubMed ID: 30177525
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
